Priors rates this Likely — 72 out of 100, updated weekly. Probably — but it is not fully settled. On the claim that next-generation CFTR modulators (vanzacaftor/tezacaftor/deutivacaftor) achieve superior CFTR correction to ETI in in vitro studies and phase 2 clinical data, with potential for once-daily dosing, its four-agent AI review panel weighs the published, peer-reviewed evidence.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Cystic Fibrosis Treatment review.